PASADENA, Calif, March 27, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE” or the "Company”) (Nasdaq: ...

A groundbreaking study published in Research (2025, DOI: 10.34133/research.0545) has elucidated the molecular mechanisms by which protein phosphatase 2A (PP2A) regulates CD8+ T cell-mediated immune ...

The FDA has granted orphan drug designation to PEP-010 for pancreatic cancer, advancing its development as a potential novel ...

Therapy receives FDA Orphan Drug Designation for PEP-010for treatment of Pancreatic CancerParis (France), March 17, 2025 – ...

a protein phosphatase (PP2A) inhibitor that has been found to be effective in cancer treatment in combination with immunotherapy. As published in BioXriv, scientists at the Netherlands Cancer ...

a protein phosphatase (PP2A) inhibitor that has been found to be effective in cancer treatment in combination with immunotherapy. As published in BioXriv, scientists at the Netherlands Cancer ...

该研究发现内皮PP2A通过抑制钙蛋白酶2的活性来维持MPST介导的H2S的产生，这对预防神经元损失和认知功能障碍是必要的。PP2A-MPST转导通路有望成为减轻脑血管损伤的潜在治疗靶点。值得注意的是，在本研究中，作者使用了汉恒生物提供的腺相关病毒AAV9-Tie-Cre、AAV9 ...

Detailed price information for Lixte Biotech Hlds (LIXT-Q) from The Globe and Mail including charting and trades.

Protein phosphatase 2A (PP2A) holoenzymes target broad substrates by recognizing short motifs via regulatory subunits. PP2A methylesterase 1 (PME-1) is a cancer-promoting enzyme and undergoes ...

Although we found that protein levels were broadly stable, our analysis reveals that dynamic waves of phosphorylation underlie each meiotic stage. We found that the phosphatase PP2A-B55 is reactivated ...